Physician profile
Cihan Cevik
NPI 1619169596
$63,998.93
in general payments reported to CMS, 2019-2025
18 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,421 · 2021: $14K · 2022: $8,874 · 2023: $11K · 2024: $5,186 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $12K · Food and Beverage: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,790 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,492 · Consulting Fee: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $11,516.18 |
| Food and Beverage | $10,322.62 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,790.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,491.50 |
| Consulting Fee | $323.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22,206.29 | 2021-2025 | Onyx Frontier, Symplicity G3, Resolute Onyx |
| Cardiovascular Systems INC. | $14,252.79 | 2019-2023 | Diamondback Coronary |
| Medtronic Vascular, INC. | $7,319.34 | 2019-2020 | |
| Abbott Laboratories | $6,707.87 | 2019-2025 | Triclip, Mitraclip, Amplatzer Talisman |
| Abiomed | $5,341.31 | 2020-2025 | Impella |
| Boston Scientific Corporation | $2,599.13 | 2019-2025 | Avvigo Guidance System, Eluvia, General - Angioplasty |
| Edwards Lifesciences Corporation | $1,503.86 | 2019-2025 | Sapien 3 Ultra Resilia, Evoque, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| W. L. Gore & Associates, INC. | $1,167.60 | 2019-2025 | Gore Cardioform Septal Occluder |
| Penumbra, INC. | $1,013.54 | 2023 | Indigo System |
| Shockwave Medical, INC | $728.09 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Asahi Intecc USA, INC. | $644.98 | 2019-2024 | Asahi Ptca Guide Wire, Peripheral Vascular |
| Csl Behring | $120.62 | 2022 | |
| Organogenesis INC. | $119.81 | 2023 | Puraply |
| Astrazeneca Pharmaceuticals LP | $111.81 | 2020 | |
| Acutus Medical, INC. | $91.46 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $33.44 | 2019 | |
| Philips North America LLC | $20.86 | 2024 | (Bq9) Coronary Ivus |
| Terumo Medical Corporation | $16.13 | 2025 | Azur Cx Detachable |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cihan Cevik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.